Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 7/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472878 | 0.91 | CHRM4 (0.48) | SSTR4SSTR1IDO1CHRM2CHRM4 | |
| SCHEMBL22449311 | 0.87 | IDO1 (0.42) | SSTR4SSTR1PDE10AIDO1CHRM2 | |
| SCHEMBL27176076 | 0.79 | CHRM4 (0.40) | PDE10AIDO1CHRM2CHRM4 | |
| SCHEMBL22472943 | 0.78 | ALDH1A1 (0.38) | CHRM2CHRM4 | |
| SCHEMBL21597912 | 0.78 | CHRM4 (0.47) | IDO1CHRM2CHRM4 | |
| SCHEMBL20473483 | 0.78 | CHRM2 (0.49) | CHRM2CHRM4 | |
| SCHEMBL15942408 | 0.77 | CHRM4 (0.66) | CHRM2CHRM4 | |
| SCHEMBL7957728 | 0.77 | IDO1 (0.38) | IDO1 | |
| SCHEMBL22472923 | 0.75 | HTR1A (0.47) | PDE10A | |
| SCHEMBL15942379 | 0.74 | CHRM4 (0.56) | CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SSTR4 234/4885SSTR1 207/4885PDE10A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.